DDInter1494 DDInter899
Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Posaconazole {u} (Compound) resembles {v} (Compound) Itraconazole
Posaconazole {u} (Compound) binds {v} (Gene) ABCB1
Posaconazole {u} (Compound) is included by {v} (Pharmacologic Class) Azoles
Posaconazole {u} (Compound) causes {v} (Side Effect) Kidney function abnormal
Posaconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Posaconazole {u} may lead to a major life threatening interaction when taken with {v} Panobinostat
Posaconazole {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Posaconazole (Compound) resembles Itraconazole (Compound)
Posaconazole (Compound) binds ABCB1 (Gene)
Posaconazole (Compound) is included by Azoles (Pharmacologic Class)
Posaconazole (Compound) causes Kidney function abnormal (Side Effect)
Posaconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine
Posaconazole may lead to a major life threatening interaction when taken with Panobinostat
Posaconazole may lead to a major life threatening interaction when taken with Leflunomide